Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
Authors:
- 2 August 2013
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 12 (6) , 881-895
Abstract
Introduction: Amphotericin B (AmB) was first approved by the US Food and Drug Administration in 1959 with sodium deoxycholate (DAmB, Fungizone®). Extensive toxicities associated with the drug led to the development of lipid formulations of AmB, including liposomal amphotericin B (L-AmB, AmBisome®). Phase I studies as well as comparative Phase III clinical trials indicate that L-AmB is associated with less nephrotoxicity and reduced infusion-related toxicity. There is, however, no recent comprehensive review of the safety and tolerability of L-AmB. Areas covered: This article reviews the safety, tolerability and the mechanisms of the major toxicities associated with L-AmB, including nephrotoxicity, infusion-related reactions (IRRs), anemia and thrombocytopenia, and hepatic abnormalities. The article further discusses the mechanism of action and pharmacokinetics of L-AmB. Expert opinion: L-AmB is a broad-spectrum antifungal agent that has significantly reduced toxicities compared to its predecessor, DAmB.Keywords
This publication has 112 references indexed in Scilit:
- Amphotericin primarily kills yeast by simply binding ergosterolProceedings of the National Academy of Sciences, 2012
- Apoptosis in Candida biofilms exposed to amphotericin BJournal of Medical Microbiology, 2010
- Amphotericin B-Induced Renal Tubular Cell Injury Is Mediated by Na+Influx through Ion-Permeable Pores and Subsequent Activation of Mitogen-Activated Protein Kinases and Elevation of Intracellular Ca2+ConcentrationAntimicrobial Agents and Chemotherapy, 2009
- Tumor necrosis factor-α induces renal vasoconstriction as well as natriuresis in miceAmerican Journal of Physiology-Renal Physiology, 2008
- Potential Basis for Amphotericin B Resistance in Aspergillus terreusAntimicrobial Agents and Chemotherapy, 2008
- A Post-PKS Oxidation of the Amphotericin B Skeleton Predicted to be Critical for Channel Formation Is Not Required for Potent Antifungal ActivityJournal of the American Chemical Society, 2007
- Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1Blood, 2006
- Hepatotoxicity Associated with Antifungal Therapy after Bone Marrow TransplantationClinical Infectious Diseases, 2005
- Role of Macrophages in the Candidacidal Activity of Liposomal Amphotericin BThe Journal of Infectious Diseases, 1997
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levelsMycoses, 1995